Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
547 stopped studies mapped to Malignant Nervous System Neoplasm and descendants · 90% state a reason
Over the 547 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT03690869 | REGN2810 in Pediatric Patients With Relapsed, Refractory Solid, or Central Nervous System… | Phase 1 / Phase 2 | terminated | Oct 1, 2018 | Regeneron Pharmaceuticals | Sponsor Decision | Sponsor / business decision |
| NCT02584647 | PLX3397 Plus Sirolimus in Unresectable Sarcoma and Malignant Peripheral Nerve Sheath…(PLX3397) | Phase 1 / Phase 2 | terminated | Oct 22, 2015 | Gulam Manji | Poor enrollment | Enrollment / accrual |
| NCT02100891 | Phase 2 STIR Trial: Haploidentical Transplant and Donor Natural Killer Cells for Solid…(STIR) | Phase 2 | terminated | Apr 1, 2014 | Monica Thakar | 15 patients enrolled out of planned 20, terminated due to slow enrollment at end of study | Enrollment / accrual |
| NCT04239040 | GVAX Plus Checkpoint Blockade in Neuroblastoma | Phase 1 | terminated | Jan 23, 2020 | Dana-Farber Cancer Institute | Manufacturing issues | Drug supply |
| NCT04469699 | Stereotactical Photodynamic Therapy With 5-aminolevulinic Acid (Gliolan®) in Recurrent…(NOA11) | Phase 2 | terminated | Jul 14, 2020 | University Hospital Muenster | Poor recruitment | Enrollment / accrual |
| NCT04897880 | A Study of Panobinostat in Pediatric Patients With Solid Tumors Including MRT/ATRT(NORTH) | Phase 2 | terminated | May 24, 2021 | Australian & New Zealand Children's Haematology/Oncology Group | Drug supply | Drug supply |
| NCT05457959 | Peptide-Pulsed Dendritic Cell Vaccination in Combination With Nivolumab and Ipilimumab… | Phase 1 | withdrawn | Jul 14, 2022 | Jonsson Comprehensive Cancer Center | Never opened | Other (stated, no rule matched) |
| NCT05737212 | Studying the Safety, Efficacy, and Pharmacokinetic Characteristics of BNCT in Patients… | Phase 1 / Phase 2 | terminated | Feb 21, 2023 | Dawonmedax Co., Ltd. | The Phase 1 clinical trial was completed, and the study was stopped to initiate a Phase 2 trial… | Other (stated, no rule matched) |
| NCT02722512 | Trial of Heat Shock Protein Peptide Complex-96 (HSPPC-96) Vaccine | Phase 1 | terminated | Mar 30, 2016 | Ann & Robert H Lurie Children's Hospital of Chicago | Lack of substantial evidence for immune responses in response to vaccination. | Other (stated, no rule matched) |
| NCT03016091 | A Trial of Pembrolizumab for Refractory Atypical and Anaplastic Meningioma | Phase 2 | terminated | Jan 10, 2017 | Rabin Medical Center | Slow accrural, dismal results | Enrollment / accrual |
| NCT03416530 | ONC201 in Pediatric H3 K27M Gliomas | Phase 1 | terminated | Jan 31, 2018 | Jazz Pharmaceuticals | The Sponsor terminated the study to prioritize enrollment in a randomized Phase 3 trial of ONC201… | Safety / toxicity |
| NCT04047602 | Radiosurgery Dose Reduction for Brain Metastases on Immunotherapy (RADREMI): A…(RADREMI) | N/A | terminated | Aug 7, 2019 | Indiana University | trial stopped due to low accrual | Enrollment / accrual |
| NCT05324501 | A Study of Intra-tumoral Administered MTX110 in Patients With Recurrent Glioblastoma(MAGIC-G1) | Phase 1 | terminated | Apr 12, 2022 | Biodexa Pharmaceuticals | Strategic decision | Sponsor / business decision |
| NCT01814813 | Vaccine Therapy With Bevacizumab Versus Bevacizumab Alone in Treating Patients With… | Phase 2 | terminated | Mar 20, 2013 | Alliance for Clinical Trials in Oncology | DSMB futility analysis | Efficacy / futility |
| NCT06233903 | 18F-mFBG Expression in Neural Crest Tumors and Organs Innervated by the Sympathetic… | Phase 2 | withdrawn | Jan 31, 2024 | Innervate Radiopharmaceuticals LLC (Formerly: Illumina Radiopharmaceuticals LLC) | Logistical considerations | Other (stated, no rule matched) |
| NCT03717142 | Feasibility of the LUM Imaging System for Detection of Cancer to the Brain | N/A | terminated | Oct 24, 2018 | Lumicell, Inc. | Initial data indicated a change in study design required prior to collecting additional data. | Other (stated, no rule matched) |
| NCT04397679 | Partial Brain RT, Temozolomide, Chloroquine, and TTF Therapy for the Treatment of Newly… | Phase 1 | terminated | May 21, 2020 | Barbara Ann Karmanos Cancer Institute | slow accrual | Enrollment / accrual |
| NCT06308575 | A Phase II Study of Rivoceranib for Patients With Recurrent or Metastatic Olfactory… | Phase 2 | withdrawn | Mar 13, 2024 | M.D. Anderson Cancer Center | PI Request--No Patient Accrual | Enrollment / accrual |
| NCT06328036 | Testing the Combination of Anti-cancer Drugs Tiragolumab and Atezolizumab to Improve… | Phase 2 | withdrawn | Mar 25, 2024 | National Cancer Institute (NCI) | Other - Protocol moved to Disapproved | Other (stated, no rule matched) |
| NCT02525692 | Oral ONC201 in Adult Recurrent Glioblastoma | Phase 2 | terminated | Aug 17, 2015 | Jazz Pharmaceuticals | The Sponsor terminated the study to prioritize enrollment in a randomized Phase 3 trial of ONC201… | Safety / toxicity |
| NCT05500508 | Oral AMXT 1501 Dicaprate in Combination With IV DFMO | Phase 1 / Phase 2 | terminated | Aug 15, 2022 | Aminex Therapeutics, Inc. | Required re-formulation of DFMO from IV to capsule to maintain safety | Safety / toxicity |
| NCT04029688 | A Study Evaluating the Safety, Tolerability, Pharmacokinetics and Preliminary Activity of… | Phase 1 / Phase 2 | terminated | Jul 23, 2019 | Hoffmann-La Roche | Study was terminated by the sponsor based on insufficient tolerability and efficacy to proceed… | Efficacy / futility |
| NCT04771897 | A Study of BXQ-350 in Children With Newly Diagnosed Diffuse Intrinsic Pontine Glioma…(KONQUER) | Phase 1 | terminated | Feb 25, 2021 | Bexion Pharmaceuticals, Inc. | Bexion Pharmaceuticals has decided to close the BXQ-350.AD study to enrollment prior to the… | Enrollment / accrual |
| NCT04421378 | A Study of Selinexor in Combination With Standard of Care Therapy for Newly Diagnosed or… | Phase 1 / Phase 2 | terminated | Jun 9, 2020 | Karyopharm Therapeutics Inc | Upon further consideration of the existing data and the competitive landscape, Karyopharm… | Other (stated, no rule matched) |
| NCT05973903 | Lenvatinib, Pembrolizumab, and Tumor Treating Fields (TTFields) for Second-line Treatment… | Phase 1 / Phase 2 | withdrawn | Aug 3, 2023 | Tel Aviv Medical Center | It was decided by the researcher not to open the study due to administrative issues. | Other (stated, no rule matched) |
| NCT04128774 | Function and Composition of Regulatory B Cells in Participants With Glioblastoma(GBMdexaB) | — | terminated | Oct 16, 2019 | Amsterdam UMC, location VUmc | To few participants | Other (stated, no rule matched) |
| NCT05879120 | Randomized Study of Neo-adjuvant and Adjuvant Pembrolizumab With and Without Targeted… | Phase 2 | withdrawn | May 30, 2023 | M.D. Anderson Cancer Center | PI Request | Other (stated, no rule matched) |
| NCT02372409 | Using MRI-Guided Laser Heat Ablation to Induce Disruption of the Peritumoral Blood Brain… | Phase 2 | terminated | Feb 26, 2015 | Washington University School of Medicine | Low accruals and competing clinical trials | Enrollment / accrual |
| NCT03973918 | Study of Binimetinib With Encorafenib in Adults With Recurrent BRAF V600-Mutated HGG(BRAF) | Phase 2 | terminated | Jun 4, 2019 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | NCI decided to terminate ABTC Consortium due to NCI moving in different direction for Brain Cancer | Other (stated, no rule matched) |
| NCT04521946 | Chemotherapy and Donor Stem Transplant for the Treatment of Patients With High Grade… | Phase 1 | withdrawn | Aug 21, 2020 | M.D. Anderson Cancer Center | No participants enrolled. | Enrollment / accrual |
| NCT04952571 | Combined Treatment of Camrelizumab and Bevacizumab for Adult Patients with Recurrent… | Phase 2 | terminated | Jul 7, 2021 | Beijing Sanbo Brain Hospital | Lack of funds | Funding |
| NCT03990597 | StrataXRT in Preventing Radiation Dermatitis in Pediatric Patients Undergoing Radiation… | Phase 1 | withdrawn | Jun 19, 2019 | M.D. Anderson Cancer Center | Per PI | Other (stated, no rule matched) |
| NCT03363659 | Disulfiram and Copper Gluconate With Temozolomide in Unmethylated Glioblastoma Multiforme | Phase 2 | terminated | Dec 6, 2017 | Wake Forest University Health Sciences | Investigator decision | Investigator |
| NCT06625359 | High-dose Chemotherapy with Thiotepa, Busulfan, and Cyclophosphamide Followed by… | Phase 2 | terminated | Oct 3, 2024 | Seoul National University Hospital | slow enrollment | Enrollment / accrual |
| NCT01246869 | Assessment of Primary and Metastatic Brain Tumor Hypoxia With Fluoromisonidazole, FDG and… | Phase 1 | terminated | Nov 23, 2010 | University of Utah | PI retired, study closed | Other (stated, no rule matched) |
| NCT04753658 | Real World Data Collection Pediatric Neuroblastoma Treated With Lorlatinib | — | terminated | Feb 15, 2021 | Pfizer | The study was prematurely discontinued due to operational implementation challenges and… | Other (stated, no rule matched) |
| NCT05123534 | A Phase 2 Study of Sonodynamic Therapy Using SONALA-001 and Exablate 4000 Type 2.0 in… | Phase 2 | suspended | Nov 17, 2021 | SonALAsense, Inc. | The study is suspended due to lack of funding but not due to safety concerns. | Safety / toxicity |
| NCT05773664 | Dexamethasone and Azeliragon for Management of Post-Resection Cerebral Edema in Patients… | Phase 1 | withdrawn | Mar 17, 2023 | City of Hope Medical Center | Funding | Funding |
| NCT00555399 | Vorinostat, Isotretinoin and Temozolomide in Adults With Recurrent Glioblastoma… | Phase 1 / Phase 2 | terminated | Nov 8, 2007 | M.D. Anderson Cancer Center | No Sponsor funding for continuation of trial | Funding |
| NCT03539731 | [18F]DASA-23 and PET Scan in Evaluating Pyruvate Kinase M2 Expression in Patients With… | Phase 1 | terminated | May 29, 2018 | Guido A. Davidzon, MD, SM | study did not meet its objectives due to difficulties in enrollment | Enrollment / accrual |
| NCT06182410 | Defibrotide Prophylaxis of Transplant Associated-Thrombotic Microangiopathy for… | Phase 2 | withdrawn | Dec 26, 2023 | University of California, San Francisco | Industry sponsor decision | Sponsor / business decision |
| NCT01483820 | Safety and Efficacy Study of TPI-287 in Neuroblastoma and Medulloblastoma | Phase 1 / Phase 2 | terminated | Dec 1, 2011 | Giselle Sholler | Lack of enrollment | Enrollment / accrual |
| NCT01505608 | Randomized Efficacy Study of TPI 287 to Treat Primary Refractory or Early Relapsed… | Phase 1 / Phase 2 | terminated | Jan 6, 2012 | Giselle Sholler | Lack of Enrollment | Enrollment / accrual |
| NCT02630043 | Trial of Tolcapone With Oxaliplatin for Neuroblastoma | Phase 1 | terminated | Dec 15, 2015 | Giselle Sholler | Lack of study enrollment | Enrollment / accrual |
| NCT06335745 | PediCARE Health Equity Intervention in High-Risk Neuroblastoma | N/A | withdrawn | Mar 28, 2024 | Dana-Farber Cancer Institute | Study halted prematurely, prior to enrollment of first participant | Enrollment / accrual |
| NCT04324840 | A Study of CC-90010 in Combination With Temozolomide With or Without Radiation Therapy in… | Phase 1 | terminated | Mar 27, 2020 | Celgene | Business objectives have changed | Sponsor / business decision |
| NCT05370508 | A Study of Sonodynamic Therapy Using SONALA-001 and Exablate 4000 Type 2.0 in Subjects… | Phase 1 / Phase 2 | terminated | May 11, 2022 | SonALAsense, Inc. | Study is terminated due to funding challenges and not due to safety concerns. | Safety / toxicity |
| NCT04047303 | CNS Penetration, PK and PD of Preoperative CC-90010 in Progressive/Recurrent Diffuse… | Phase 1 | terminated | Aug 6, 2019 | Celgene | Business objectives have changed. | Sponsor / business decision |
| NCT03250299 | Microtubule-Targeted Agent BAL101553 and Radiation Therapy in Treating Patients With… | Phase 1 | terminated | Aug 15, 2017 | Basilea Pharmaceutica | Due to the National Cancer Institute's (NCI)-mandated termination of the Adult Brain Tumor… | Other (stated, no rule matched) |
| NCT04221061 | 18F-FluorThanatrace (PET/CT) in Glioblastoma | Early Phase 1 | terminated | Jan 9, 2020 | University of Pennsylvania | Companion treatment trial closed early with negative results. No imaging study participants… | Other (stated, no rule matched) |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Apr 8, 2025source: clinicaltrials